Related Experiment Video
Updated: May 5, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.2K
Antiplatelet therapy to prevent recurrent stroke: Three good options
Atizazul H Mansoor1, Mohammad T Mujtaba, Brian Silver
1Department of Cardiovascular Services, PinnacleHealth Cardiac and Vascular Institute, PinnacleHealth Hospitals, Harrisburg, PA.
Cleveland Clinic Journal of Medicine
|December 6, 2013
Summary
Antiplatelet drugs like aspirin, dipyridamole, and clopidogrel are crucial for preventing recurrent ischemic strokes caused by atherosclerosis. This review examines their current uses and supporting evidence.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Ischemic stroke poses a significant risk for recurrence, particularly in atherosclerotic origins.
- Antiplatelet therapy is a cornerstone in managing patients post-stroke to prevent further vascular events.
Purpose of the Study:
- To review the current indications for antiplatelet agents.
- To examine the evidence supporting the use of aspirin, dipyridamole, and clopidogrel in preventing recurrent ischemic stroke.
Main Methods:
- Literature review of clinical trials and guidelines.
- Analysis of evidence for aspirin, dipyridamole, and clopidogrel efficacy.
- Discussion of current therapeutic recommendations.
Main Results:
- Aspirin, dipyridamole, and clopidogrel are established therapies for secondary stroke prevention.
- Evidence supports their role in reducing the risk of recurrent ischemic events.
- Specific indications and contraindications guide their clinical application.
Conclusions:
- Antiplatelet drugs are essential in the secondary prevention of atherosclerotic ischemic stroke.
- Understanding the evidence base is critical for optimizing patient outcomes.
- Continued evaluation of these agents ensures effective therapeutic strategies.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:27Peripheral Artery Disease III: Interprofessional Care
655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:27Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444